Inhibition of hERG channel trafficking: An under-explored mechanism for drug-induced QT prolongation

ChemMedChem

Volumn 3, Issue 10, 2008, Pages 1501-1502

  Yeung, Kap Sun ^a   Meanwell, Nicholas A ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Cell surface expression; Drug safety; hERG channels; Ion channels; Long QT syndrome

Indexed keywords

ERG1 POTASSIUM CHANNEL; FLUOXETINE; ION CHANNEL; KETOCONAZOLE; POTASSIUM CHANNEL HERG;

CHEMICALLY INDUCED DISORDER; CHEMISTRY; DRUG ANTAGONISM; HUMAN; IC 50; LONG QT SYNDROME; METABOLISM; PROTEIN TRANSPORT; SHORT SURVEY;

ETHER-A-GO-GO POTASSIUM CHANNELS; FLUOXETINE; HUMANS; INHIBITORY CONCENTRATION 50; ION CHANNELS; KETOCONAZOLE; LONG QT SYNDROME; PROTEIN TRANSPORT;

EID: 54849435649     PISSN: 18607179     EISSN: 18607187     Source Type: Journal    
DOI: 10.1002/cmdc.200800170     Document Type: Short Survey

References (17)

1. a) M. C. Sanguinetti, M. Tristani-Firouzi, Nature 2006, 440, 463-469;
2. b) B. Fermini, A. A. Fossa, Nat. Rev. Drug Discovery 2003, 2, 439-447.
3. S. Dalibalta, J. S. Mitcheson in Antitargets: Prediction and Prevention of Drug Side Effects (Eds.: R. J. Vaz, T. Klabunde), Wiley-VCH, Weinheim, 2008, pp. 89-108.
4. Heat shock protein 90 (Hsp90) inhibitor gel-danamycin and arsenic trioxide have both been shown to inhibit hERG trafficking by inhibiting the formation of the hERG-Hsp90 complex; a) E. Ficker, A. T. Dennis, L. Wang, A. M. Brown, Circ. Res. 2003, 92, e87-e100;
5. b) E. Ficker, Y. A. Kuryshev, A. T. Dennis, C. Obejero-Paz, L. Wang, P. Hawryluk, B. A. Wible, A. M. Brown, Mol. Pharmacol. 2004, 66, 33-44;
6. c) A. Dennis, L. Wang, X. Wan, E. Ficker, Biochem. Soc. Trans. 2007, 35, 1060-1063.
7. C. L. Anderson, B. P. Delisle, B. D. Anson, J. A. Kilby, M. L. Will, D. J. Tester, Q. Gong, Z. Zhou, M. J. Ackerman, C. T. January, Circulation 2006, 113, 365-373.
8. H. Takemasa, T. Nagatomo, H. Abe, K. Kawakami, T. Igarashi, T. Tsurugi, N. Kabashima, M. Tamura, M. Okazaki, B. P. Delisle, C. T. January, Y. Qtsuji, Br. J. Pharmacol. 2008, 153, 439-447.
9. S. Rajamani, L. L. Eckhardt, C. R. Valdivia, C. A. Klemens, B. M. Gillman, C. L. Anderson, K. M. Holzem, B. P. Delisle, B. D. Anson, J. C. Makielski, C. T. January, Br. J. Pharmacol. 2006, 149, 481-489.
10. B. A. Wible, P. Hawryluk, E. Ficker, Y. A. Kuryshev, G. Kirsch, A. M. Brown, J. Pharmacol. Toxicol. Methods 2005, 52, 136-145.
11. a) J. S. Cordes, Z. Sun, D. B. Lloyd, J. A. Bradley, A. C. Opsahl, M. W. Tengowski, X. Chen, J. Zhou, Br. J. Pharmacol. 2005, 145, 15-23;
12. b) Y. A. Kuryshev, E. Ficker, L. Wang, P. Hawryluk, A. T. Dennis, B. A. Wible, A. M. Brown, J. Kang, X.-L. Chen, K. Sawamura, W. Reynolds, D. Rampe, J. Pharmacol. Exp. Ther. 2005, 312, 316-323.
13. J. Guo, H. Massaeli, W. Li, J. Xu, T. Luo, J. Shaw, L. A. Kirshenbaum, S. Zhang, J. Pharmacol. Exp. Ther. 2007, 321, 911-920.
14. L. Wang, B. A. Wible, X. Wan, E. Ficker, J. Pharmacol. Exp. Ther. 2007, 320, 525-534.
15. H. Sun, X. Liu, Q. Xiong, S. Shikano, M. Li, J. Biol. Chem. 2006, 281, 5877-5884.
16. N.-S. Mok, Y.-K. Lo, P.-T. Tsui, C.-W. Lam, J. Cardiovasc. Electrophysiol. 2005, 16, 1375-1377.
17. M. A. Quadrel, S. H. Atkin, M. A. Jaker, Am. Heart J. 1992, 123, 1377-1379.